naquotinib
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
1
Phase 4
0
Earliest trial started Jan 23, 2014 (NCT02192697)
Timeline
Indications
Mechanism of action
- Epidermal growth factor receptorINHIBITOR
Epidermal growth factor receptor inhibitor
Epidermal growth factor receptor erbB1 inhibitor
Active against WT and variant EGFR. Increased activity against activating and resistance mutants vs. wild-type target.
Chemistry & pharmacology
Loading structure…
SMILES
C=CC(=O)N1CC[C@@H](Oc2nc(Nc3ccc(N4CCC(N5CCN(C)CC5)CC4)cc3)c(C(N)=O)nc2CC)C1- Mol. weight
- 562.72 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3663929 ↗
Also known as
- asp8273
- asp8273
- naquotinib
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03082300 | Phase 1 | Mar 21, 2017 | Astellas |
| NCT03042013 | Phase 2 | Feb 28, 2017 | Astellas |
| NCT02674555 | Phase 1 | Aug 31, 2016 | Astellas |
| NCT02588261 | Phase 3 | Feb 10, 2016 | Astellas |
| NCT02500927 | Phase 2 | Jun 25, 2015 | Astellas |
| NCT02113813 | Phase 1 | Apr 23, 2014 | Astellas |
| NCT02192697 | Phase 1/Phase 2 (Phase 2) | Jan 23, 2014 | Astellas |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Astellas | For profit | 7 | 7 | 3 | 2014 |
1 organizations
Page 1 / 1